News

BeiGene, Ltd. a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, announced a collaboration and license agreement with…
Read More...

Rocket Pharmaceuticals, Inc. a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces the Company’s…
Read More...

Sanofi and Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, have…
Read More...

GSK and Medicines for Malaria Venture (MMV) announced that the Australian Therapeutic Goods Administration (TGA) accepted the submission of a Category 1 application to extend the…
Read More...

Humanigen, Inc. (HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug…
Read More...

Celularity Inc. and GX Acquisition Corp announced they have entered into a definitive merger agreement pursuant to which GX Acquisition Corp. will combine with Celularity. Upon the…
Read More...

Affinivax, Inc. a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS (Multiple Antigen Presenting System) platform, announced…
Read More...

Teva Pharmaceuticals Industries Ltd. and MedinCell announced positive results for study TV46000-CNS-30072 (the RISE study – The Risperidone Subcutaneous Extended-Release Study), a Phase…
Read More...

Pfizer Inc. announced that the first participant has been dosed in the Phase 3 CIFFREO study, which will evaluate the efficacy and safety of investigational gene therapy candidate…
Read More...

BlueRock Therapeutics, a preclinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, in collaboration with Memorial Sloan Kettering Cancer Center (MSK),…
Read More...

Bayer has signed a collaboration and services agreement with CureVac N.V. a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic…
Read More...

Merck, a leading science and technology company, today announced the acquisition of AmpTec, a leading Hamburg, Germany-based, mRNA contract development and manufacturing organization…
Read More...

ImaginAb Inc. announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. to supply 89Zr CD8 Immuno-PET agent, which can be used to image CD8 T cells in cancer…
Read More...

Almirall, S.A. a global biopharmaceutical company based in Barcelona, and Tyris Therapeutics, a next-generation gene therapy company founded by Columbus Venture Partners, have announced…
Read More...

AM-Pharma B.V., an emerging leader focused on the treatment of kidney disease, sepsis and organ injury, announced that the first patients with COVID-19 infection and sepsis-associated…
Read More...

Xencor, Inc. a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and The University of Texas MD…
Read More...

A new COVID-19 drug screening and resistance hub will be established in Scotland, based at the MRC-University of Glasgow Centre for Virus Research (CVR). The ground-breaking project,…
Read More...

RedHill Biopharma Ltd. a specialty biopharmaceutical company, today announced that RHB-204 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for its…
Read More...

Dewpoint Therapeutics, the biomolecular condensates company, announced a new research collaboration with Pfizer for the development of potential therapeutics for the treatment of…
Read More...

Morphic Therapeutic a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, announced the expansion of its…
Read More...